Madrigal Pharmaceuticals with ticker code (MDGL) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 230 and 123 with the average target price sitting at 170. Now with the previous closing price of 118.34 this is indicating there is a potential upside of 43.7%. The day 50 moving average is 120.66 and the 200 moving average now moves to 114.83. The company has a market capitalisation of $1,824m. Company Website: http://www.madrigalpharma.com
The potential market cap would be $2,621m based on the market concensus.
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) Ã-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-Ã-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
